Peter Diamandis built an empire that now points its full force at the biggest prize of all: reversing human aging. Here's why that matters more than you think.
# The Empire of XPRIZE: From Space to LongevityPeople often ask me who the most influential people in longevity are. Beyond the usual suspects — David Sinclair with his sirtuins and books, Vadim Gladyshev with the deepest theoretical work on aging clocks anyone has produced, George Church with his improbable ability to spawn entire industries from a single Harvard lab, and, in AI-driven drug discovery, your humble servant — there is a unifying figure whose fingers are in every pie. A man who is not a scientist, not a clinician, not a drug developer, and yet somehow sits at the center of the entire web.
That man is Peter Diamandis.
You can love him or criticize him — and plenty of people do both, loudly — but the facts are undeniable. Peter has built several empires and helped propel dozens of companies from a napkin sketch into production-stage businesses. Insilico Medicine, the company I co-founded, is one of them. He pulled us into rooms we would never have walked into on our own. He introduced founders to capital, capital to founders, and ideas to people willing to back them with money rather than tweets.
And of all the empires Peter has built — Singularity University, Abundance360, Fountain Life, Human Longevity Inc., Celularity, BOLD Capital — the most ambitious, the most public, and arguably the most consequential is the XPRIZE.
To understand why the XPRIZE matters, you have to understand the operating system Peter runs. He is not a researcher. He doesn't run a wet lab. He doesn't publish in Cell. What he does — and what almost nobody else in the world does at his scale — is connect billionaire capital to frontier science at exactly the right moment. He is a catalyst, in the chemical sense. He doesn't become part of the reaction. He just makes it go a thousand times faster.
The Peterverse is a network. Ray Kurzweil sits in it. So does Elon Musk. Tony Robbins. George Church. Bob Hariri. Craig Venter. Every billionaire-curious-about-longevity I have ever met has either been to an Abundance360 event, sits on a Fountain Life patient list, or has shaken Peter's hand at a private dinner in Beverly Hills. He is the human router for the entire frontier-tech longevity stack.
And the XPRIZE is his most public instrument for shaping what frontier means.
The origin story is by now a Silicon Valley campfire tale, but it bears repeating because it explains everything Peter has done since.
In 1994, Peter — frustrated that the space industry he had grown up worshipping had calcified into a NASA-and-Boeing duopoly — read Charles Lindbergh's autobiography, The Spirit of St. Louis. Buried in the book was a detail most readers would skim past: Lindbergh's 1927 transatlantic flight had been catalyzed by the Orteig Prize, a $25,000 purse offered by hotel owner Raymond Orteig in 1919 for the first nonstop flight between New York and Paris. Nine teams competed. They collectively spent roughly $400,000 — sixteen times the prize value — chasing it. Lindbergh won. And the modern aviation industry, almost overnight, exploded into existence.
Peter's insight was simple but revolutionary: incentive prizes catalyze 10 to 50 times their face value in R&D spending, attract teams who would never apply for a government grant, and most importantly, they shift the question from "who deserves funding?" to "who can actually do it?"
In 1996, on a stage in St. Louis, Peter announced the Ansari XPRIZE: $10 million for the first private team to build a reusable spacecraft, fly it to 100 km altitude, return it safely, and repeat the feat within two weeks. He did not have the $10 million. He didn't have anywhere close to it. He spent years scrambling, eventually backstopping the prize with an aviation insurance policy and the Ansari family's check.
Nobody believed it. Airlines laughed. NASA ignored it. Aerospace executives told reporters the whole thing was a publicity stunt by a Greek-American doctor who had read too much science fiction.
On October 4, 2004, Burt Rutan's SpaceShipOne, funded by Paul Allen, flew to space twice in five days and won the prize. Twenty-six teams from seven countries had competed. They had collectively spent over $100 million chasing $10 million.
And then the world changed. Richard Branson licensed the technology and started Virgin Galactic. Jeff Bezos accelerated Blue Origin. Elon Musk — already running SpaceX — pointed to the Ansari as proof of concept that private space was real. Today the commercial space industry is worth hundreds of billions of dollars annually, and SpaceX alone has rewritten the economics of orbital launch.
One $10 million prize. One hundred million dollars of catalyzed R&D. A multi-trillion-dollar industry.
The model worked.
After Ansari, Peter went on a tear. The XPRIZE Foundation has now launched more than 25 competitions, with over $300 million in prize purses, drawing more than 1,000 teams across every continent. A partial list:
The Google Lunar XPRIZE ($30M) for the first private team to soft-land a rover on the Moon. The Qualcomm Tricorder XPRIZE ($10M) for a Star Trek-style portable diagnostic device — the winning device, Final Frontier Medical's DxtER, can diagnose more than a dozen conditions from a patient's home. The NRG COSIA Carbon XPRIZE ($20M) for converting CO₂ emissions into useful products. Feed the Next Billion ($15M) for cultivated and plant-based meat alternatives. The Rainforest XPRIZE ($10M) for autonomous biodiversity surveying. The IBM Watson AI XPRIZE for AI applied to humanity's grand challenges. The ANA Avatar XPRIZE ($10M) for telepresence robotics. XPRIZE Wildfire ($11M) for autonomous wildfire detection and suppression. And the headline-grabber: the Musk Foundation Carbon Removal XPRIZE at a stunning $100 million, until recently the largest incentive prize in history.
Each of these has the same structure. Define a measurable, audacious goal. Set a deadline. Put up real money. Let the world's weirdest, smartest, most stubborn teams self-organize to chase it. Let the best one win. The losers, in the meantime, have collectively built a new industry around the problem.
Having served on several XPRIZE projects and boards over the years — most recently on the Scientific Advisory Board of the XPRIZE for Healthspan — I can tell you that the public-facing version of XPRIZE is only half the story. The other half is what happens in the rooms.
An XPRIZE Scientific Advisory Board is not like an NIH study section. It is not like a corporate R&D committee. It is, in my experience, the closest thing in modern science to what I imagine the early Royal Society felt like. Every top expert in the relevant field is in the room — either as a judge, as a board member, or as a competing team principal. Nobody is filling out a grant application. Nobody is worried about their tenure case. Nobody is hedging.
The questions in those meetings are uncomfortable in the best way:
What would we actually measure? What would constitute proof? How do we write rules that are fair, but ambitious enough that a winner means something? What's the minimum viable demonstration that would convince a skeptic? How do we prevent gaming?
I have sat through SAB discussions where Nobel laureates, biotech CEOs, and 28-year-old founders argued for hours about a single endpoint. About whether grip strength counts as muscle function. About whether DNA methylation clocks are robust enough to be a primary outcome or only a secondary. About whether you should reward the team that achieves the most reversal in a single biomarker, or the team that achieves moderate reversal across the most biomarkers. These are exactly the conversations the field needs to be having in public, and almost never has, because academic incentives reward incremental papers and pharma incentives reward whatever the FDA happens to accept that decade.
XPRIZE forces the field to commit. It makes us write down, in advance, what we will accept as victory. That alone is worth more than most NIH consortia produce in a decade.
In November 2023, Peter announced the XPRIZE Healthspan — a $101 million purse, the largest single XPRIZE ever, eclipsing even the Musk Foundation carbon prize. Backed by Hevolution, Chip Wilson, and a coalition of longevity-curious philanthropists, it is the first incentive prize in history that takes aging itself as its target.
The goal, stripped to its essence: demonstrate a therapeutic intervention that, in adults aged 65 to 80, restores muscle, cognitive, and immune function by at least 10 years — and ideally by 20 years — within a treatment window of one year or less.
Read that again. One year of treatment. Twenty years of biological reversal. In humans. In a clinical trial. With prespecified, composite endpoints across three organ systems.
This is not a mouse experiment. This is not "rapamycin extended median lifespan in C57BL/6 by 14%." This is human data, in a real population, with regulatory-grade rigor, on a seven-year timeline.
The prize structure rewards a tiered outcome — partial credit for 10 years of reversal, more for 15, the full $81 million top prize for 20 — across a composite score that integrates muscle function (think grip strength, gait speed, sit-to-stand), cognitive performance (validated batteries for memory, processing speed, executive function), and immune function (vaccine response, inflammatory markers, immune cell composition). There are also milestone awards along the way to keep teams in the game.
Why does this matter? Because the longevity field has, for two decades, been allergic to commitment. We have papers. We have hypotheses. We have vibes. We have endless arguments about whether epigenetic clocks measure aging or measure something correlated with aging. We have podcasts. What we do not have, and what the field has desperately needed, is a concrete, falsifiable, public goal that the entire community has agreed in advance constitutes proof.
The XPRIZE Healthspan is that goal. Either a team will demonstrate 20 years of functional reversal in humans by 2030, or they won't. There will be no hand-waving. There will be no "well, in mice…" There will be a number, on a leaderboard, audited by judges who have spent years agreeing on the rules.
That is what the field has needed since I entered it twenty years ago.
Let me be direct about the criticism, because there is plenty of it and some of it lands.
Peter is not a scientist. He is, by training, an MD with an aerospace engineering degree, and he has not personally run a clinical trial or sequenced a genome. His public persona is relentlessly optimistic — sometimes uncomfortably so. Critics call him a hype machine, a salesman, a man who oversells the timeline on every technology he touches. Some of his ventures have struggled. Human Longevity Inc., founded with Craig Venter, never quite became the population-genomics colossus it promised to be. Some of his communications border on the millenarian.
I'll grant most of that. I have rolled my eyes at certain Peter slides. I have winced at certain Peter timelines. I have watched him pitch ideas that were not yet ready to be pitched.
And I do not care. Because the results speak.
SpaceShipOne flew. The Tricorder works — and a real device based on the winning team's design is in clinical use. Carbon removal is a real industry now, and a substantial fraction of the founders in it cite the XPRIZE as why they entered the field. Fountain Life, his longevity diagnostics chain, has put thousands of asymptomatic adults through full-body MRIs and discovered cancers and aneurysms that would otherwise have killed them. Insilico Medicine, where I am CEO, would not be where it is today without his network. I say that as a fact, not flattery.
Peter's superpower is not that he is right about every technology. He isn't. His superpower is that he gets capital and talent off the sidelines. He gets the billionaire who would have spent another decade buying art to spend $10 million on a longevity bet instead. He gets the academic who would have written another R01 to start a company. He gets the engineer at Lockheed to quit and join a moonshot. He converts inertia into motion. In a field as encrusted with inertia as biomedicine, that is rarer and more valuable than a Nature paper.
His critics, I notice, have not built anything that flew to space, diagnosed your aneurysm, or put $101 million on the table to reverse aging.
Let me close with predictions, because forecasts unaccompanied by accountability are just talk, and I have always preferred talk that can be checked later.
First, the XPRIZE Healthspan will force the field to converge on what to measure. This is, quietly, the most important thing it will accomplish. For two decades the longevity field has been split into tribes — the methylation clock people, the senescence people, the mTOR people, the reprogramming people, the metabolic people — each measuring different things and each implicitly claiming theirs is the master variable. The XPRIZE rules will not pick a tribe, but they will define a composite endpoint that all tribes have to compete on. Within five years, that composite, or something close to it, will be the de facto standard for aging interventions. Regulators will follow.
Second, the prize will create direct competition among approaches that have, until now, mostly ignored each other. Small molecules versus partial reprogramming versus senolytics versus gene therapy versus combinations. The teams that win will almost certainly be the teams that combine approaches, because no single intervention will move muscle, cognition, and immunity by 20 years. This is what I have been saying for a decade and what AI-driven drug discovery is finally making feasible: aging is not one disease, it is a network, and the winning therapy will be a designed combination of agents discovered, optimized, and dosed by AI.
Third, the prize will attract non-traditional teams. AI companies. Biotech startups that would never have existed without the prize as their North Star. Gene therapy outfits. Possibly even garage biologists with a clever idea about thymus regeneration. This is the Ansari pattern: the winner of the space prize was not Boeing or Lockheed, it was Burt Rutan in a hangar in Mojave. The winner of Healthspan will probably not be Pfizer.
Fourth, and most importantly, the prize will set a concrete, falsifiable goal. Twenty years of reversal. Either you did it or you didn't. No more "directionally promising." No more "trending toward significance." No more "the mice looked younger." A number, a population, a deadline.
My prediction: a team will achieve at least 10 years of composite reversal within the seven-year window, claiming a substantial milestone prize. The full 20-year reversal is harder — I would put it at roughly 30% probability by 2030, and roughly 70% probability by 2035 if the field is given a follow-on prize. The winning team will not be a single academic lab. It will be a biotech, probably backed by AI-driven drug discovery, running a combination protocol that includes a senolytic, a partial reprogramming agent or its small-molecule analog, and a metabolic regulator, on top of aggressive lifestyle and diagnostic monitoring of the kind Fountain Life pioneered.
I would not be shocked, in fact, if the winning team has had Peter Diamandis in the room at some point in its origin story. The Peterverse, after all, is large.
Twenty years ago, when I started in longevity, the field was a backwater. Serious scientists avoided the word "anti-aging" the way physicists avoid "free energy." Today, $101 million sits on the table for whoever can reverse aging in humans by twenty years, and the most distinguished researchers in the field are arguing in good faith about whether grip strength or gait speed is the better muscle endpoint. That shift did not happen on its own. It happened because a small number of people refused to accept that aging was untouchable, and because at least one of them — a doctor-engineer who once read a book about Lindbergh — had the particular and unusual gift of getting other people to write large checks toward audacious goals.
Peter Diamandis is not the smartest person in longevity. He is not the deepest. He is not the most rigorous. But he may be the most consequential, because he has done the thing that the field needed someone to do and that no scientist could have done from inside the academy: he has turned aging into a competition with a scoreboard, a prize purse, and a deadline.
The empire of XPRIZE went from space to genomes to carbon to fire to aging. It will, I suspect, go further still — to consciousness, to whole-body cryopreservation, to brain-computer interfaces, to whatever the next impossible thing is.
And whichever team finally walks across the stage in 2030 or 2031 to claim the Healthspan prize, they will owe a small but real piece of their victory to the man who decided, sometime around 1994, that the most efficient way to change the future was to put a price on it.
I, for one, am glad he did.
Forever.AI · Alex Zhavoronkov, PhD · May 2026
Select All (Cmd+A) → Copy → Paste into Substack